



Press Release

Statutory information

IBA – YEAR-END RESULTS FOR 2008

GROWTH OVER 50%
CASH-FLOW SOLID
PROPOSED DIVIDEND OF EUR 0.08 PER SHARE

Embargo until 5:40 PM (Belgian time) – March 5, 2009

Louvain-la-Neuve, Belgium, March 5, 2009 – IBA (Ion Beam Applications S.A.) presented its consolidated results today for the year ended December 31, 2008.

KEY FACTS AND FIGURES

The year's main event for 2008 was incontestably the acquisition on June 1st. of CISBIO, a French medical diagnostics company with over 600 staff and a turnover of over EUR 100 million, in which IBA already had a 19.9 % holding.

Highlights of IBA results for 2008:

Sales up 55.5% at EUR 332.6 million. With a like-for-like basis and constant exchange rate, growth was 23%.

- Recurring earnings before amortizations and immobilizations (REBITDA) were EUR 31.8 million: a strong increase of 74.1% in relation to 2007.
- A pre-tax profit of EUR 12.1 million which was almost double that of 2007. This is due:
 - on the one hand to recurring earnings (REBIT) of EUR 10.8 million, down 8.8 % in relation to 2007 in real terms, but equivalent to 2007 at a constant exchange rate, mainly reflecting the depreciation of the dollar;
 - on the other hand to non recurring earnings of EUR 6.4 million largely explained by the finalization of the integration of CISBIO into the IBA perimeter during the year.
- A total tax charge of EUR 6.8 million contrasting with the fiscal revenue of EUR 7.0 millions arising from the significant activation of deferred taxes (EUR 9.4 million) posted in 2007.
- A net profit of EUR 5.3 million, as against EUR 13.9 million in 2007, taking into account the exceptional difference in fiscal charges between the 2 financial years.
- A positive current liquidity of 53.9 million gross, and 17.8 million net.
- A solid order book backlog for equipment amounting to EUR 177 million.



Press Release |

Statutory information

RESULTS BY BUSINESS AREA

Following the acquisition of CISBIO at the end of May 2008, whose figures were consolidated into in IBA group as from 1 June 2008, the financial reporting of IBA is presented in two business areas: Pharmaceuticals on the one hand and Equipment on the other.

Breakdown of the year's facts and figures by business area:

PHARMACEUTICALS

- This area consists of the production and distribution of radiopharmaceutical agents mainly for use in diagnostics and in the treatment of cancer.
- The turnover for the Pharmaceuticals sector is up 91.6%, achieving EUR 150.0 million in 2008 compared to EUR 78.3 million in 2007.
- Through the acquisition of CISBIO, IBA has considerably extended its product range, particularly in the field of conventional nuclear medicine as well as in the field of in vitro testing and screening. A number of these products benefit from significant commercial and R&D synergies with the activities of IBA.
- During 2008, IBA reinforced the extension of its FDG [fluorodeoxyglucose] production and distribution world-wide. At the end of 2008, this amounted to 47 production centers for FDG, of which 17 in North America, 21 in Europe and 9 in Asia; or an increase of 12 production centers in relation to the end of 2007. Among these production units, IBA is not involved in 10 of the production units but 10 of these form part of the world-wide radiopharmaceutical distribution network via various collaborative agreements such as the agreement signed in September 2008 with Hae Dong Co. Ltd. relating to distribution in South Korea or the agreement signed in December 2008 with Biotech Cyclotron of Texas for the Western United States.
- 2008 also saw the signature of the first agreements aimed at positioning IBA in the field of patented radiopharmaceutical tracers likely to use the company's network of PET centers. An agreement has thus been signed with the Wilex AG companies to acquire the distribution rights of REDECTANE® – an imaging diagnostic agent currently in Phase III, based on a positron emitter intended to help doctors to diagnose clear cell renal cancers before surgery. Another agreement has been signed with Aposense® (formerly NST Ltd.), for the labeling and distribution of APOSENSE® [18F]-ML-10, the new apoptosis molecular imaging agent.



Press Release |

Statutory information

EQUIPMENT

- This business area covers:
 - Proton therapy;
 - Particle accelerators (cyclotrons, Rhodotron®, Dynamitron®, etc...);
 - Dosimetry;
 - Related service business activities.

- The Equipment business area turnover is in organic growth at 34.7%, attaining EUR 182.6 million in 2008 compared to EUR 135.6 million in 2007.

- Proton therapy:
 - In 2008, despite the difficult financial environment, IBA concluded with Treatment Center Inc. the financing of the proton therapy project at the Central DuPage Hospital in Chicago and was selected by the same client to equip the proton therapy center at William Beaumont Hospital in Royal Oak, Michigan, USA. Turnover continues to grow strongly (+45.2%) following progress on projects underway signed in 2006 and 2007.
 - During previous years, IBA had invested heavily in research and development for proton therapy, translated into a strong growth in expenditure for 2008 but, amongst other things, in mid-December 2008 has enabled us to obtain the American Food and Drug Administration (FDA) authorization for this mode of treatment by Pencil Beam Scanning (PBS) intended for proton therapy. Pencil Beam Scanning technology was developed by IBA in close collaboration with the Massachusetts General Hospital (MGH) team at the Francis H. Burr Proton Therapy Center in Boston, USA where the first patient was treated using this method in December 2008. It enables refinement to an unparalleled degree of the precision with which the treatment beam can target cancerous cells. This is a world first for a treatment system based on a cyclotron.


- Accelerators:
 - Orders for 18 PET and SPECT cyclotrons were received during 2008, in other words more or less at the same level as the 19 orders received in 2007.
 - Nine sales of electron accelerators (Rhodotron® and Dynamitron®) for industrial applications were also concluded in 2008, including the first X-ray sterilization system which uses the Rhodotron® TT-1000, sold to the LEONI Group in Switzerland. This is an excellent performance compared to the 3 machines sold in 2007.

- Dosimetry:
 - Dosimetry sales grew by 6.6% in 2008, following on, amongst others, from the 12 first orders for the new COMPASS® dosimetry solution and the success experienced in Asia and in the United States. The development of a first dosimetry system for proton therapy is also worthy of note.

Press Release

Statutory information

DISTRIBUTION OF CONSOLIDATED SALES BY BUSINESS AREA



RESULTS IN DETAIL

	Dec-31-2008 (EUR 000)	Dec-31-2007 (EUR 000)	Variation (EUR 000)	%
Revenues	332,607	213,849	118,758	55.5%
REBITDA	31,798	18,269	13,529	74.1%
<i>% of revenues</i>	<i>9.56%</i>	<i>8.54%</i>		
REBIT	10,751	11,788	-1,037	-8.8%
<i>% of revenues</i>	<i>3.23%</i>	<i>5.51%</i>		
Profit Before Taxes	12,110	6,862	5,248	76.5%
<i>% revenues</i>	<i>3.64%</i>	<i>3.21%</i>		
Net Results	5,300	13,930	-8,630	-62.0%
<i>% revenues</i>	<i>1.59%</i>	<i>6.51%</i>		

REBITDA: Recurrent Earnings Before Interest, Taxes, Depreciation and Amortization.

REBIT: Recurrent Earnings Before Interest and Taxes.

The average USD/EUR exchange rate for the year was \$1.4712 to 1 Euro against \$1.37 to 1 Euro the year before, or a dollar depreciation of 7.4%. At a constant exchange rate, the increase in revenue would have been 59%, and of the recurrent earnings before interest, taxes, depreciation and amortization (REBITDA) would have been 86% and the reduction in recurrent earnings 1.6%. Almost 50% of IBA's activities have been historically influenced by the American dollar. This proportion has been significantly reduced by the consolidation of the CISBIO business activity.



Press Release

Statutory information

OPERATING RESULTS

Gross margin was EUR 112.3 million, up 60.8% on 2007. As a percentage of sales, the gross margin was 33.8% for 2008 compared to 32.7% in 2007.

The 75% increase in operating costs mainly reflects the change in perimeter arising from the integration of CISBIO as from 1 June 2008.

In 2008 IBA's recurrent earnings were EUR 10.8 million compared to EUR 11.8 million for the previous year or a fall of 8.8%. At a constant EUR/USD constant exchange rate, recurrent earnings would have shown a fall of 1.6%.

OTHER NON-RECURRING INCOME AND EXPENSE

Non-recurring results for the year 2008 were EUR 6.4 million and mainly reflect the effects of the acquisition of CISBIO and in particular a contribution of EUR 14 million from the French CEA [Atomic Energy Commission] intended to assist CISBIO in fulfilling its obligations in terms of the dismantling of certain installations in Saclay after 2017, coupled with various amortizations of tangible and intangible assets.

FINANCIAL RESULTS

The financial results show a charge of EUR 2.6 million arising from the balance between revenue from short-term cash investments, charges relating to updating long-term provisions, interest charges on financial debts and the revaluation of financial instruments. In particular, the company had invested a minimum portion of its cash assets in investment instruments which, due to the financial crisis have had to be revalued at their presumed market value. At the close of the financial year these were reduced to a value under EUR 0.7 million and are classified with long-term assets.

TAXES

Taxes for 2008 show a charge of EUR 6.8 million in comparison to earnings of EUR 7.0 million in 2007. 2007 was atypical following the activation of significant deferred taxes. Given the existence of these deferred taxes, the 2008 charge mainly represents the normal use of previously constituted assets and thus the company's cash flow is only very slightly affected by this charge.

PROFIT (LOSS) FROM ENTITIES ACCOUNTED FOR UNDER THE EQUITY METHOD

This heading which shows a charge of EUR 2.4 million, mainly consists of the results of CISBIO for the 5 first months of 2008, particularly affected during this period by the provision for restructuring posted by CISBIO in February 2008.

NET INCOME

Net income was EUR 5.3 million for 2008, down on the net income of EUR 13.9 million in 2007, mainly due to technical movements of deferred taxes.

DIVIDEND

Given the good performance and cash flow of the company, the Board of Directors has decided to put before the Ordinary General Meeting of 13 May 2009 the proposal to pay a dividend of EUR 0.08 per share. Despite the recurrent earnings remaining at the same level as in 2007, this reduction in



Press Release

Statutory information

dividend in relation to the EUR 0.17 per share paid in 2008, is proposed with a view to prudence in the light of the uncertainty of the general economic environment.

In accordance with Article 8 of the statutes and regulations currently in force, the IBA Board of Directors which will meet on March 17 has set April 30, 2009 as the date from which bearer securities will be cancelled and replaced by dematerialized or registered securities. From this date, the exercising of rights (receiving dividends, voting rights, etc.,...) relating to bearer securities not converted into dematerialized or bearer shares will be suspended until their conversion into one or the other of these forms referred to above.

EVENTS SUBSEQUENT TO THE END OF THE REPORTING PERIOD

At the beginning of February 2009, IBA and Eczacıbası-Monrol Nuclear Products A.S. joined forces to develop the PET (Positron Emission Tomography) and SPECT (Single photon emission computed tomography) radiopharmaceuticals market in the Balkans, Middle East, North Africa and in Central and Eastern Europe. This means that the IBA PET radiopharmaceuticals production and distribution network will be supported by 52 installations throughout the world.

SHAREHOLDER'S CALENDAR

Interim management statement, first quarter of 2009	May 12, 2009
2009 General Meeting	May 13, 2009, 10:00 AM
Announcement of results for six-month period ended June 30, 2009	August 31 2009
Interim management statement, third quarter of 2009	November 18, 2009
Announcement of results for year ended December 31, 2009	March, 15 2010

Press Release

Statutory information

REPORT OF THE AUDITOR



ERNST & YOUNG

Ernst & Young
Réviseurs d'Entreprises
Bedrijfsrevisoren
De Kleetlaan 2
B - 1831 Diegem
Tel: +32 (0)2 774 91 11
Fax: +32 (0)2 774 90 90
www.ey.com/be

To the Board of Directors of Ion Beam Applications SA


We have not yet delivered our audit report on the annual consolidated accounts of your company for the year ended 31 December 2008. We confirm that our audit work has not revealed any significant matters requiring adjustments to the accounting information included in this press release.

In compliance with article 8, §6, 2nd part of the Royal Decree of 31 March 2003 concerning the duties of an issuer of financial instruments admitted on a Belgian regulated market, you have to include the following information in the annual press release:

"The auditor has confirmed that his audit work has not revealed any significant matters requiring adjustments to the accounting information included in this press release."

Brussels, 3 march 2009

Ernst & Young Réviseurs d'Entreprises scrl
Commissaire
represented by



Eric Golenvaux
Partner



Press Release |

Statutory information

OUTLOOK

In the current difficult economic climate, from mid-2008, management established the measures necessary to reinforce control of expenditure, undertakings and investments, and currently, the company is glad to see that an increasing proportion of its activities are recurrent and/or fall within a sector described as “defensive” (healthcare). In 2008, recurrent business activity represented 62% of the group’s total (67% with CISBIO over 12 months) and this means that we can look calmly towards 2009. The level of growth may however be affected by the financial crisis, in particular in the proton therapy equipment sector where sales achieved are often linked to our clients’ ability to obtain financing. Overall, the Group feels that it can maintain its level of profitability during 2009 and remains confident in the medium term of achieving its objective of 10% operating profit while accepting that its expectation could be slightly put back in time.

ABOUT IBA

IBA develops and sells advanced technologies, pharmaceuticals and tailored solutions for healthcare, with the emphasis on diagnostics and the treatment of cancer. IBA’s scientific expertise also means that it is active in the field of industrial sterilization and ionization. IBA is listed on the pan-European stock exchange EURONEXT and belongs to the BelMid index (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Website : <http://www.iba-worldwide.com>

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Tel.: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com



Press Release

Statutory information

CONSOLIDATED INCOME STATEMENTS

	31/12/08	31/12/07	Variation	
	(EUR '000)	(EUR '000)	(EUR '000)	%
Sales and contract revenue	332,607	213,849	118,758	55.5%
Cost of sales and contract costs	220,272	144,004	76,268	53.0%
Gross profit/(loss)	112,335	69,845	42,490	60.8%
	33.8%	32.7%		
Selling and marketing expenses	30,368	21,105	9,263	43.9%
General and administrative expenses	44,215	19,785	24,430	123.5%
Research and development expenses	27,001	17,167	9,834	57.3%
Recurring expenses	101,584	58,057	43,527	75.0%
Recurring profit/(loss)	10,751	11,788	-1,037	-8.8%
	3.2%	5.5%		
Other non-recurring (income)/ expenses - net	-6,359	4,748	-11,107	-233.9%
Finance (income)/ expenses - net	2,637	456	2,181	478.3%
Share of (profit)/loss of equity-accounted companies	2,363	-278	2,641	-950.0%
Profit/(loss) before tax	12,110	6,862	5,248	76.5%
Tax (income)/ expenses	6,781	-6,983	13,764	-197.1%
Profit/ (loss) for the period from continuing operations	5,329	13,845	-8,516	-61.5%
Equity Holders of the parent	5,300	13,930	-8,630	-62.0%
Minority interests	29	-84		
Profit/(loss) for the period	5,329	13,846		
REBITDA	31,798	18,269	13,529	74.1%



Press Release

Statutory information

CONSOLIDATED BALANCE SHEET

	31/12/08	31/12/07	
	(EUR '000)	(EUR '000)	
ASSETS			
Goodwill	28,762	26,538	2,224
Other intangible assets	37,768	4,619	33,149
Property, plant and equipment	78,693	59,792	18,901
Investments accounted for using the equity method	6,063	8,381	-2,318
Deferred tax assets	33,986	33,312	674
Other long-term receivables	65,111	18,641	46,470
Non-current assets	250,383	151,283	99,100
Inventories and contracts in progress	85,759	40,899	44,860
Accounts receivable	74,820	44,243	30,577
Other receivables	42,341	27,943	14,398
Derivative financial instruments Assets	2,275	1,860	415
Cash and cash equivalents	53,943	58,210	-4,267
Current assets	259,138	173,155	85,983
Total assets	509,521	324,438	185,083
EQUITY AND LIABILITIES			
Share capital	37,285	36,215	1,070
Share premium	124,358	115,199	9,159
Treasury shares	-7,563	-6,746	-817
Net gains on available-for-sales financial investments	0	0	0
Hedging and other reserves	9,220	8,397	823
Cumulative translation differences	-17,064	-12,309	-4,755
Retained earnings	5,446	70	5,376
Capital and reserves attributable to Company's equity holders	151,682	140,826	10,856
Minority interests	684	655	29
TOTAL EQUITY	152,366	141,481	10,885
Borrowings	11,885	17,854	-5,969
Deferred tax liabilities	470	369	101
Provisions	98,371	12,313	86,058
Other long-term liabilities	45,515	33,763	11,752
Non-current liabilities	156,241	64,299	91,942
Borrowings	24,252	8,328	15,924
Other short-term financial liabilities	2,498	0	2,498
Accounts payable	71,518	51,191	20,327
Current income tax liabilities	1,942	1,115	827
Other payables and accruals	100,704	58,024	42,680
Current liabilities	200,914	118,658	82,256
Total liabilities	357,155	182,957	174,198
Total equity and liabilities	509,521	324,438	185,083

Press Release

Statutory information

CONSOLIDATED CASH FLOW TABLE

	31/12/08	31/12/07
	(EUR '000)	(EUR '000)
Cash flow from operating activities		
Net profit/(loss) for the period	5,300	13,930
Adjustments for:		
Depreciation and impairment of property, plant and equipment	12,586	5,755
Amortization and impairment of intangible assets	3,404	1,554
Write-off on receivables	1,122	-1,489
Changes in fair value of financial assets (gains)/losses	3,897	6
Changes in provisions	2,148	2,546
Taxes	6,781	-6,983
Share of result of associates and joint ventures accounted for using the equity method	2,363	-280
Other non cash items	2,927	540
Net profit/(loss) before changes in working capital	40,528	15,579
Trade receivables, other receivables, and deferrals	-6,394	-25,218
Inventories and contract in progress	-28,414	1,177
Trade payables, other payables, and accruals	8,515	28,771
Change in working capital	-26,293	4,730
Income tax paid/received, net	-1,647	-1,701
interest paid	1,944	1,747
interest received	-2,616	-2,321
Net cash (used in)/generated from operations	11,916	18,034
Cash flow from investing activities		
Acquisitions of property, plant, and equipment	-18,672	-21,668
Acquisitions of intangible assets	-6,043	-2,104
Disposals of fixed assets	2,866	324
Acquisitions of subsidiaries, net of acquired cash	47,195	51
Acquisitions of third party and equity-accounted companies	-4,375	0
Disposals of subsidiaries and equity-method-accounted companies, net of assigned cash	0	1
Acquisition of non-current financial assets and loans granted	-34,076	
Other investing cash flows	-8,986	1,050
Net cash (used in)/generated from investing activities	-22,091	-22,346
Cash flow from financing activities		
Proceeds from borrowings	11,162	9,400
Repayments of borrowings	-10,810	-8,173
Interest paid	-1,944	-1,747
Interest received	2,616	2,321
Capital increase (or proceeds from issuance of ordinary shares)	10,050	1,905
Purchase of treasury shares	-818	-6,490
Dividends paid	-4,018	0
Other financing cash flows	-934	287
Net cash (used in)/generated from financing activities	5,304	-2,497
Net cash and cash equivalents at the beginning of the year	58,210	67,600
Changes in net cash and cash equivalents	-4,871	-6,809
Exchange gains/(losses) on cash and cash equivalents	604	-2,581
Net cash and cash equivalent at the end of the year	53,943	58,210